Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors

par Clynes, Raphael, Calvani, Nicola, Croker, Byron P, Richards, Hanno B
Publié 2005

Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus

par Richards, Hanno B., Satoh, Minoru, Shaw, Melody, Libert, Claude, Poli, Valeria, Reeves, Westley H.
Publié 1998

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

par Kivitz, Alan J., Wagner, Ulf, Dokoupilova, Eva, Supronik, Jerzy, Martin, Ruvie, Talloczy, Zsolt, Richards, Hanno B., Porter, Brian
Publié dans Rheumatol Ther (2018)

Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus

par Li, Yi, Lee, Pui Y, Sobel, Eric S, Narain, Sonali, Satoh, Minoru, Segal, Mark S, Reeves, Westley H, Richards, Hanno B
Publié 2009

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

par Tahir, Hasan, Deodhar, Atul, Genovese, Mark, Takeuchi, Tsutomu, Aelion, Jacob, Van den Bosch, Filip, Haemmerle, Sibylle, Richards, Hanno B.
Publié dans Rheumatol Ther (2017)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis

par van der Heijde, Désirée, Braun, Jürgen, Deodhar, Atul, Baraliakos, Xenofon, Landewé, Robert, Richards, Hanno B, Porter, Brian, Readie, Aimee
Publié dans Rheumatology (Oxford) (2019)

Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases

par Yamasaki, Yoshioki, Narain, Sonali, Hernandez, Liza, Barker, Tolga, Ikeda, Keigo, Segal, Mark S, Richards, Hanno B, Chan, Edward KL, Reeves, Westley H, Satoh, Minoru
Publié 2006

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)

par Deodhar, Atul A., Dougados, Maxime, Baeten, Dominique L., Cheng‐Chung Wei, James, Geusens, Piet, Readie, Aimee, Richards, Hanno B., Martin, Ruvie, Porter, Brian
Publié dans Arthritis Rheumatol (2016)

Effect of an Exogenous Trigger on the Pathogenesis of Lupus in (NZB × NZW)F(1) Mice

par Yoshida, Hideo, Satoh, Minoru, Behney, Krista M., Lee, Chee-Gun, Richards, Hanno B., Shaheen, Victoria M., Yang, Jun-Qi, Singh, Ram R., Reeves, Westley H.
Publié 2002

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

par Pavelka, Karel, Kivitz, Alan J., Dokoupilova, Eva, Blanco, Ricardo, Maradiaga, Marco, Tahir, Hasan, Wang, Yi, Porter, Brian O., Stefanska, Anna, Richards, Hanno B., Rohrer, Susanne
Publié dans ACR Open Rheumatol (2020)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

par van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
Publié dans Arthritis Rheumatol (2016)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Stu...

par Deodhar, Atul, Blanco, Ricardo, Dokoupilová, Eva, Hall, Stephen, Kameda, Hideto, Kivitz, Alan J., Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Richards, Hanno B., Haemmerle, Sibylle, Braun, Jürgen
Publié dans Arthritis Rheumatol (2020)